BRAF with or without MEK inhibition plus PD-1 checkpoint blockade for the treatment of metastatic melanoma.

被引：1

作者：

Rohlfs, Michelle ^{[1
]}

Bassett, Roland L. ^{[1
]}

Lacey, Carol ^{[1
]}

McQuail, Natalie ^{[1
]}

Mehta, Urvi ^{[1
]}

John, Ida ^{[1
]}

Simien, Rinata ^{[1
]}

Tupue, Stephanie ^{[1
]}

Dett, Tina Karin ^{[1
]}

Glitza, Isabella Claudia ^{[1
]}

Diab, Adi ^{[1
]}

Amaria, Rodabe Navroze ^{[1
]}

Tawbi, Hussein Abdul-Hassan ^{[1
]}

Davies, Michael A. ^{[1
]}

Hwu, Wen-Jen ^{[1
]}

Hwu, Patrick ^{[1
]}

Patel, Sapna Pradyuman ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期

关键词：

D O I：

10.1200/JCO.2016.34.15_suppl.9548

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9548

引用

页数：2

共 50 条

[21] BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma
Richman, Juliet
Martin-Liberal, Juan
Diem, Stefan
Larkin, James
EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (09) : 1285 - 1297
[22] Successful Treatment of Myasthenia Gravis Following PD-1/CTLA-4 Combination Checkpoint Blockade in a Patient With Metastatic Melanoma
Werner, Jan-Michael
Schweinsberg, Viola
Schroeter, Michael
von Reutern, Boris
Malter, Michael P.
Schlaak, Max
Fink, Gereon R.
Mauch, Cornelia
Galldiks, Norbert
FRONTIERS IN ONCOLOGY, 2019, 9
[23] Biology of PD-1 Checkpoint Blockade
Sharpe, Arlene H.
BLOOD, 2017, 130
[24] HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade
Woods, David M.
Sodre, Andressa L.
Villagra, Alejandro
Sarnaik, Amod
Sotomayor, Eduardo M.
Weber, Jeffrey
CANCER IMMUNOLOGY RESEARCH, 2015, 3 (12) : 1375 - 1385
[25] Complete Remission of a metastatic malignant Melanoma by the PD-1 Antibody Pembrolizumab after BRAF Inhibition and Ipilimumab
Alhumam, A.
Haalck, T.
Ruhde, L.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2017, 15 : 169 - 170
[26] Comprehensive Clinical Trial Data Summation for BRAF-MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma
Luke, Jason J.
ONCOLOGIST, 2019, 24 (11): : E1197 - E1211
[27] BRAF and NRAS mutation status and response to checkpoint inhibition in advanced melanoma.
van Not, Olivier Jules
van den Eertwegh, Alfonsus Johannes Maria
Haanen, John B. A. G.
Blank, Christian U.
Aarts, Maureen J. B.
van den Berkmortel, Franchette
de Groot, Jan Willem
Hospers, Geke
Kapiteijn, Ellen
Piersma, Djura
Van Rijn, Rozemarijn
Stevense, Marion
Van Der Veldt, Astrid Aplonia Maria
Vreugdenhil, Gerard
Boers-Sonderen, Marye
Bonenkamp, Han J.
Jansen, Anne M. L.
Blokx, Willeke
Wouters, Michel W. J. M.
Suijkerbuijk, Karijn
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[28] COMBINED BRAF AND MEK INHIBITION IMPROVES OUTCOME IN METASTATIC MELANOMA
不详
CANCER DISCOVERY, 2012, 2 (11) : 971 - 971
[29] PD-1 inhibition in congenital pigment synthesizing metastatic melanoma
Weyand, Angela C.
Mody, Rajen J.
Rabah, Raja M.
Opipari, Valerie P.
PEDIATRIC BLOOD & CANCER, 2018, 65 (01)
[30] Efficacy of immunotherapy and sequencing of checkpoint inhibition for metastatic ocular melanoma.
Abhyankar, Anuja
Maharaj, Satish
Miller, Donald M.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

← 1 2 3 4 5 →